US Stock MarketDetailed Quotes

CLDX Celldex Therapeutics

Watchlist
  • 20.570
  • +0.260+1.28%
Close Feb 28 16:00 ET
  • 20.570
  • 0.0000.00%
Post 16:59 ET
1.37BMarket Cap-8.40P/E (TTM)

Celldex Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
1.99%7.02M
-71.56%1.18M
110.35%3.19M
832.09%2.5M
-83.87%156K
192.02%6.88M
156.11%4.13M
272.73%1.52M
64.42%268K
455.75%967K
Operating revenue
1.99%7.02M
-71.56%1.18M
110.35%3.19M
832.09%2.5M
-83.87%156K
192.02%6.88M
156.11%4.13M
272.73%1.52M
64.42%268K
455.75%967K
Cost of revenue
Gross profit
Operating expense
35.70%202.1M
45.71%57.2M
29.38%55.32M
45.83%48.82M
21.91%40.76M
36.06%148.93M
33.09%39.26M
52.14%42.76M
20.04%33.47M
39.52%33.44M
Selling and administrative expenses
24.69%38.55M
16.20%10.26M
22.30%10.05M
26.41%9.13M
37.09%9.1M
13.68%30.91M
33.84%8.83M
25.88%8.22M
0.94%7.22M
-3.92%6.64M
-General and administrative expense
24.69%38.55M
16.20%10.26M
22.30%10.05M
26.41%9.13M
37.09%9.1M
13.68%30.91M
33.84%8.83M
25.88%8.22M
0.94%7.22M
-3.92%6.64M
Research and development costs
38.59%163.55M
54.27%46.94M
31.06%45.26M
51.18%39.69M
18.15%31.66M
43.46%118.01M
32.87%30.43M
60.09%34.54M
26.63%26.25M
57.12%26.8M
Operating profit
-37.34%-195.08M
-59.50%-56.03M
-26.40%-52.13M
-39.49%-46.32M
-25.06%-40.61M
-32.63%-142.04M
-25.97%-35.13M
-48.90%-41.24M
-19.78%-33.21M
-36.47%-32.47M
Net non-operating interest income expense
Other net income (expense)
5,970.96%37.22M
209.24%8.94M
235.85%10.01M
287.53%10.48M
150.80%7.8M
111.72%613K
-685.05%-8.18M
226.64%2.98M
132.64%2.7M
318.57%3.11M
Gain on sale of security
183.80%37.22M
106.78%8.94M
235.85%10.01M
287.53%10.48M
150.80%7.8M
350.77%13.11M
209.08%4.32M
226.64%2.98M
589.54%2.7M
1,402.42%3.11M
Special income (charges)
--0
----
----
----
----
-53.60%-12.5M
----
----
----
----
-Less：Restructuring and merger&acquisition
--0
----
----
----
----
--0
----
----
----
----
-Less:Other special charges
----
----
----
----
----
-16.67%12.5M
----
----
----
----
Income before tax
-11.62%-157.86M
-8.74%-47.09M
-10.09%-42.12M
-17.51%-35.84M
-11.74%-32.81M
-25.91%-141.43M
-63.50%-43.31M
-42.85%-38.26M
15.28%-30.5M
-27.38%-29.36M
Income tax
Net income
-11.62%-157.86M
-8.74%-47.09M
-10.09%-42.12M
-17.51%-35.84M
-11.74%-32.81M
-25.91%-141.43M
-63.50%-43.31M
-42.85%-38.26M
15.28%-30.5M
-27.38%-29.36M
Net income continuous Operations
-11.62%-157.86M
-8.74%-47.09M
-10.09%-42.12M
-17.51%-35.84M
-11.74%-32.81M
-25.91%-141.43M
-63.50%-43.31M
-42.85%-38.26M
15.28%-30.5M
-27.38%-29.36M
Minority interest income
Net income attributable to the parent company
-11.62%-157.86M
-8.74%-47.09M
-10.09%-42.12M
-17.51%-35.84M
-11.74%-32.81M
-25.91%-141.43M
-63.50%-43.31M
-42.85%-38.26M
15.28%-30.5M
-27.38%-29.36M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-11.62%-157.86M
-8.74%-47.09M
-10.09%-42.12M
-17.51%-35.84M
-11.74%-32.81M
-25.91%-141.43M
-63.50%-43.31M
-42.85%-38.26M
15.28%-30.5M
-27.38%-29.36M
Basic earnings per share
16.10%-2.45
15.48%-0.71
20.99%-0.64
16.92%-0.54
9.68%-0.56
-21.67%-2.92
-50.00%-0.84
-42.11%-0.81
15.58%-0.65
-26.53%-0.62
Diluted earnings per share
16.10%-2.45
15.48%-0.71
20.99%-0.64
16.92%-0.54
9.68%-0.56
-21.67%-2.92
-50.00%-0.84
-42.11%-0.81
15.58%-0.65
-26.53%-0.62
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 1.99%7.02M-71.56%1.18M110.35%3.19M832.09%2.5M-83.87%156K192.02%6.88M156.11%4.13M272.73%1.52M64.42%268K455.75%967K
Operating revenue 1.99%7.02M-71.56%1.18M110.35%3.19M832.09%2.5M-83.87%156K192.02%6.88M156.11%4.13M272.73%1.52M64.42%268K455.75%967K
Cost of revenue
Gross profit
Operating expense 35.70%202.1M45.71%57.2M29.38%55.32M45.83%48.82M21.91%40.76M36.06%148.93M33.09%39.26M52.14%42.76M20.04%33.47M39.52%33.44M
Selling and administrative expenses 24.69%38.55M16.20%10.26M22.30%10.05M26.41%9.13M37.09%9.1M13.68%30.91M33.84%8.83M25.88%8.22M0.94%7.22M-3.92%6.64M
-General and administrative expense 24.69%38.55M16.20%10.26M22.30%10.05M26.41%9.13M37.09%9.1M13.68%30.91M33.84%8.83M25.88%8.22M0.94%7.22M-3.92%6.64M
Research and development costs 38.59%163.55M54.27%46.94M31.06%45.26M51.18%39.69M18.15%31.66M43.46%118.01M32.87%30.43M60.09%34.54M26.63%26.25M57.12%26.8M
Operating profit -37.34%-195.08M-59.50%-56.03M-26.40%-52.13M-39.49%-46.32M-25.06%-40.61M-32.63%-142.04M-25.97%-35.13M-48.90%-41.24M-19.78%-33.21M-36.47%-32.47M
Net non-operating interest income expense
Other net income (expense) 5,970.96%37.22M209.24%8.94M235.85%10.01M287.53%10.48M150.80%7.8M111.72%613K-685.05%-8.18M226.64%2.98M132.64%2.7M318.57%3.11M
Gain on sale of security 183.80%37.22M106.78%8.94M235.85%10.01M287.53%10.48M150.80%7.8M350.77%13.11M209.08%4.32M226.64%2.98M589.54%2.7M1,402.42%3.11M
Special income (charges) --0-----------------53.60%-12.5M----------------
-Less：Restructuring and merger&acquisition --0------------------0----------------
-Less:Other special charges ---------------------16.67%12.5M----------------
Income before tax -11.62%-157.86M-8.74%-47.09M-10.09%-42.12M-17.51%-35.84M-11.74%-32.81M-25.91%-141.43M-63.50%-43.31M-42.85%-38.26M15.28%-30.5M-27.38%-29.36M
Income tax
Net income -11.62%-157.86M-8.74%-47.09M-10.09%-42.12M-17.51%-35.84M-11.74%-32.81M-25.91%-141.43M-63.50%-43.31M-42.85%-38.26M15.28%-30.5M-27.38%-29.36M
Net income continuous Operations -11.62%-157.86M-8.74%-47.09M-10.09%-42.12M-17.51%-35.84M-11.74%-32.81M-25.91%-141.43M-63.50%-43.31M-42.85%-38.26M15.28%-30.5M-27.38%-29.36M
Minority interest income
Net income attributable to the parent company -11.62%-157.86M-8.74%-47.09M-10.09%-42.12M-17.51%-35.84M-11.74%-32.81M-25.91%-141.43M-63.50%-43.31M-42.85%-38.26M15.28%-30.5M-27.38%-29.36M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -11.62%-157.86M-8.74%-47.09M-10.09%-42.12M-17.51%-35.84M-11.74%-32.81M-25.91%-141.43M-63.50%-43.31M-42.85%-38.26M15.28%-30.5M-27.38%-29.36M
Basic earnings per share 16.10%-2.4515.48%-0.7120.99%-0.6416.92%-0.549.68%-0.56-21.67%-2.92-50.00%-0.84-42.11%-0.8115.58%-0.65-26.53%-0.62
Diluted earnings per share 16.10%-2.4515.48%-0.7120.99%-0.6416.92%-0.549.68%-0.56-21.67%-2.92-50.00%-0.84-42.11%-0.8115.58%-0.65-26.53%-0.62
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
LINTEX
920106
+30.00%
LINGOOD
833284
+29.98%
NTGEC
870436
+29.98%
4
CG MED EQUIP.
838810
+29.97%
5
Jiayu Holding
300117
+20.48%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025